Scalable Synthesis of ABBV-105 Enabled by Suzuki Coupling with Low Pd Loading, Ru-Catalyzed Asymmetric Hydrogenation, and Acylation Using Impinging Jet
-
Published:2024-07-17
Issue:8
Volume:28
Page:3229-3247
-
ISSN:1083-6160
-
Container-title:Organic Process Research & Development
-
language:en
-
Short-container-title:Org. Process Res. Dev.
Author:
Cardinal-David Benoit1ORCID, Shekhar Shashank1ORCID, Phillips Eric M.1ORCID, Swift Elizabeth C.1ORCID, Kotecki Brian1ORCID, Ickes Andrew R.1ORCID, Storer Gregory E.1ORCID, Caspi Daniel D.1ORCID, Verma Anuj1, Moschetta Eric G.1ORCID, Tao Daniel1, Morrill Westin H.1, Bellettini John R.1, Nordstrom Fredrik L.1ORCID, Mattei Alessandra1ORCID, Springer Kirsten1, Qiu Haixiao1, Bien Jeffrey T.1, Manjrekar Onkar1, Henry Rodger F.1, Wallace Grier A.1, Schaffter Lisa1, Voight Eric A.1ORCID
Affiliation:
1. AbbVie, Inc., 1401 Sheridan Road, North Chicago, Illinois 60064, United States
Publisher
American Chemical Society (ACS)
Reference39 articles.
1. Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease 2. The role of Bruton's tyrosine kinase in the immune system and disease 3. The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy 4. ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation 5. Bonafoux, D.; Davis, H. M.; Frank, K. E.; Friedman, M. M.; Herold, J. M.; Hoemann, M. Z.; Huntley, R.; Osuma, A.; Sheppard, G.; Somal, G. K.; Van Camp, J.; Van Epps, S. A.; Vasudevan, A.; Wallace, G. A.; Wang, Lu.; Wang, Zhi.; Wilson, N. S.; Xu, X. Primary Carboxamides as BTK Inhibitors. WO Patent WO2014210255A1, 2014.
|
|